<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HBC58582B7D91421B9BA23A47AD03FA59" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 5776 IH: Medicare and Opioid Safe Treatment Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2018-05-11</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 5776</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20180511">May 11, 2018</action-date><action-desc><sponsor name-id="N000015">Mr. Neal</sponsor> (for himself, <cosponsor name-id="H001065">Mr. Holding</cosponsor>, <cosponsor name-id="C001090">Mr. Cartwright</cosponsor>, and <cosponsor name-id="T000477">Mr. Taylor</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such
			 provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XVIII to provide for Medicare coverage of certain services furnished by opioid
			 treatment programs, and for other purposes.</official-title></form>
	<legis-body id="HA5D07A023EBC4905A75A5B0D87B77B67" style="OLC">
 <section id="H9345E3525D5742799919F615469BE64A" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Medicare and Opioid Safe Treatment Act</short-title></quote> or the <quote><short-title>MOST Act</short-title></quote>.</text> </section><section id="H0031060356BB43578CA6E115E65A718C" section-type="subsequent-section"><enum>2.</enum><header>Medicare coverage of certain services furnished by opioid treatment programs</header> <subsection id="H45CF4A57E1734FE6AFDFCE8DCB2483BD"><enum>(a)</enum><header>Coverage</header><text display-inline="yes-display-inline">Section 1861(s)(2) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(s)(2)</external-xref>) is amended—</text>
 <paragraph id="H329CAD345F274540A1FFA23FC88260CA"><enum>(1)</enum><text>in subparagraph (FF), by striking at the end <quote>and</quote>;</text> </paragraph><paragraph id="H6BE117A60D4F4BD4992DCEDE7DCA4EA2"><enum>(2)</enum><text>in subparagraph (GG), by inserting at the end <quote>; and</quote>; and</text>
 </paragraph><paragraph id="H1D37BFE978FF4874B85B04303228D122"><enum>(3)</enum><text>by adding at the end the following new subparagraph:</text> <quoted-block display-inline="no-display-inline" id="H45244F55C4AD4E24925D7A29D6C4F245" style="OLC"> <subparagraph id="HE84FE53E39D7485BBBFC6D4F6E92696D"><enum>(HH)</enum><text display-inline="yes-display-inline">opioid use disorder treatment services (as defined in subsection (jjj)).</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="HD92CC08010454B65ABCED79F060EFB3A"><enum>(b)</enum><header>Opioid use disorder treatment services and opioid treatment program defined</header><text>Section 1861 of the Social Security Act is amended by adding at the end the following new subsection:</text>
				<quoted-block display-inline="no-display-inline" id="H39AB19BC8DF94A2AABD7084D4708F0CF" style="OLC">
					<subsection id="H577CAC6A76F34546AC3E56BF9726F58E"><enum>(jjj)</enum><header>Opioid use disorder treatment services; opioid treatment program</header>
 <paragraph id="HC0F75269669C41DBA33FC901C3EA95BE"><enum>(1)</enum><header>Opioid use disorder treatment services</header><text display-inline="yes-display-inline">The term <term>opioid use disorder treatment services</term> means items and services that are furnished by an opioid treatment program for the treatment of opioid abuse disorder, including—</text>
 <subparagraph id="HA584196710E34281AF662252519EAD05"><enum>(A)</enum><text display-inline="yes-display-inline">opioid agonist treatment medications (including oral versions) that are approved by the Food and Drug Administration under section 505 of the Federal Food, Drug and Cosmetic Act for use in the treatment of opioid use disorder;</text>
 </subparagraph><subparagraph id="HF4C97220EAFD449E9BECA75FB374002A"><enum>(B)</enum><text display-inline="yes-display-inline">dispensing and administration of such medications, if applicable;</text> </subparagraph><subparagraph id="H4DE43AD0FE474BE4938EE029AFC8225C"><enum>(C)</enum><text display-inline="yes-display-inline">substance abuse counseling by a professional to the extent authorized under State law to furnish such services;</text>
 </subparagraph><subparagraph id="H5DD42CAFD95F48E995F33E5CDEC46EBD"><enum>(D)</enum><text display-inline="yes-display-inline">behavioral individual and group therapy with physicians or psychologists (or other mental health professionals to the extent authorized under State law);</text>
 </subparagraph><subparagraph id="H762554B134BA4BC99AE784020B3A9A81"><enum>(E)</enum><text display-inline="yes-display-inline">toxicology testing; and</text> </subparagraph><subparagraph id="H04F3865AF58443CF8540CBCDB36B188D"><enum>(F)</enum><text display-inline="yes-display-inline">other items and services that the Secretary determines are appropriate.</text>
 </subparagraph></paragraph><paragraph id="H00A66A3014C848DA93236D3CD47E9108"><enum>(2)</enum><header>Opioid treatment program</header><text display-inline="yes-display-inline">The term <term>opioid treatment program</term> means an opioid treatment program (as defined in section 8.2 of title 42 of the Code of Federal Regulations, or any successor regulation) that—</text>
 <subparagraph id="H3A2A340FB2A24750AB57E5E1512EDE5B"><enum>(A)</enum><text display-inline="yes-display-inline">is enrolled under section 1866(j);</text> </subparagraph><subparagraph id="HC614E26845A14012BCEA6726A9EB471B"><enum>(B)</enum><text>has in effect a certification by the Substance Abuse and Mental Health Services Administration for such a program;</text>
 </subparagraph><subparagraph id="H24BC7E890AA4403BB6599D7F3D32D2A8"><enum>(C)</enum><text>is accredited by an accrediting body approved by the Substance Abuse and Mental Health Services Administration; and</text>
 </subparagraph><subparagraph id="H4020D34B194D40B796E537D4C9BD10DE"><enum>(D)</enum><text>meets such additional conditions as the Secretary may find necessary to ensure—</text> <clause id="HEF7ED2A2BB034AD4B79BF129AE1E6B9D"><enum>(i)</enum><text display-inline="yes-display-inline">the health and safety of individuals being furnished services under such program; and</text>
 </clause><clause id="H0A02A7FE25834E75B96D174B0C2627D1"><enum>(ii)</enum><text display-inline="yes-display-inline">the effective and efficient furnishing of such services.</text> </clause></subparagraph></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block> </subsection><subsection id="HC57C2F424D4F45E99A84E4192CDB43FD"><enum>(c)</enum><header>Payment</header> <paragraph id="HA3D0FEF6188D4BF584FD6C006719D83C"><enum>(1)</enum><header>In general</header><text>Section 1833(a)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">42 U.S.C. 1395l(a)(1)</external-xref>) is amended—</text>
 <subparagraph id="H34FA949755864612AA3F5297EFF926C7"><enum>(A)</enum><text>by striking <quote>and (BB)</quote> and inserting <quote>(BB)</quote>; and</text> </subparagraph><subparagraph id="HC554289D54554D24A3CDB44AE1752FC3"><enum>(B)</enum><text>by inserting before the semicolon at the end the following <quote>, and (CC) with respect to opioid use disorder treatment services furnished during an episode of care, the amount paid shall be equal to the amount payable in accordance with section 1834(w) less any copayment required as specified by the Secretary</quote>.</text>
 </subparagraph></paragraph><paragraph id="H21CF8DBABF1B4590B577ED1555C6D2ED"><enum>(2)</enum><header>Payment determination</header><text>Section 1834 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m</external-xref>) is amended by adding at the end the following new subsection:</text>
					<quoted-block display-inline="no-display-inline" id="HB3531BAC741C4229A576227B7B8680EF" style="OLC">
						<subsection id="HBB3D62920E094A3684208AB0DDC701C4"><enum>(w)</enum><header>Opioid use disorder treatment services</header>
 <paragraph id="H84E814C08AC54CC591D600A5E53550C8"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary shall pay to an opioid treatment program (as defined in paragraph (2) of section 1861(jjj)) an amount that is equal to 100 percent of a bundled payment under this part for opioid use disorder treatment services (as defined in paragraph (1) of such section) that are furnished by such program to an individual during an episode of care (as defined by the Secretary) beginning on or after January 1, 2020. The Secretary shall ensure that no duplicative payments are made under this part or part D to a physician, practitioner, or pharmacy for items and services furnished by an opioid treatment program.</text>
 </paragraph><paragraph id="H0B53A31025994A1E9B0132C4CDE01712"><enum>(2)</enum><header>Considerations</header><text display-inline="yes-display-inline">The Secretary may implement this subsection through one or more bundles based on the type of medication provided (such as buprenorphine, methadone, naltrexone, or a new innovative drug), the frequency of services, the scope of services furnished, characteristics of the individuals furnished such services, or other factors as the Secretary determine appropriate. In developing such bundles, the Secretary may consider payment rates paid to opioid treatment programs for comparable services under State plans under title XIX, under the TRICARE program under <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/10/55">chapter 55</external-xref> of title 10 of the United States Code, or by other health care payers.</text>
 </paragraph><paragraph id="H38D2051822784829B7B03DB2D204E6F8"><enum>(3)</enum><header>Annual updates</header><text display-inline="yes-display-inline">The Secretary shall provide an update each year to the bundled payment amounts under this subsection.</text>
							</paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
 </paragraph></subsection><subsection id="H32B2F2C540064186B90F476F307B88F0"><enum>(d)</enum><header>Including opioid treatment programs as Medicare providers</header><text display-inline="yes-display-inline">Section 1866(e) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395cc">42 U.S.C. 1395cc(e)</external-xref>) is amended—</text> <paragraph id="H6F290F5584114939ADF6CC490FB0D79D"><enum>(1)</enum><text>in paragraph (2), by striking at the end <quote>and</quote>;</text>
 </paragraph><paragraph id="HDC80307F1EE440898A414C719B00ABB6"><enum>(2)</enum><text>in paragraph (3), by striking the period at the end and inserting <quote>; and</quote>; and</text> </paragraph><paragraph id="H3C65CA6B92A14BE7A6B2DE217BD066A2"><enum>(3)</enum><text>by adding at the end the following new paragraph:</text>
					<quoted-block display-inline="no-display-inline" id="H1E6AF12CA9C54F48973600308A4B0431" style="OLC">
 <paragraph id="HEBCF7E3F7F7E4A48B447921B9D3A3D4A"><enum>(3)</enum><text display-inline="yes-display-inline">opioid treatment programs (as defined in paragraph (2) of section 1861(jjj)), but only with respect to the furnishing of opioid treatment program services (as defined in paragraph (1) of such section).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
				</paragraph></subsection></section><section id="H514810B221D64C83925FFFA5B5C78891"><enum>3.</enum><header>Review and adjustment of payments under the Medicare outpatient prospective payment system to avoid
			 financial incentives to use opioids instead of non-opioid alternative
			 treatments</header>
 <subsection id="H86207B944AE549459C784756912B9D6D"><enum>(a)</enum><header>Outpatient prospective payment system</header><text display-inline="yes-display-inline">Section 1833(t) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">42 U.S.C. 1395l(t)</external-xref>) is amended by adding at the end the following new paragraph:</text>
				<quoted-block display-inline="no-display-inline" id="H41B2ED81E204440588669F67D9C74687" style="OLC">
					<paragraph id="H85A5909C8D1243FCB47C32EB6ED934AE"><enum>(22)</enum><header>Review and revisions of payments for non-opioid alternative treatments</header>
 <subparagraph id="H97B0B226A5B8421A8279CA862DF9782F"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">With respect to payments made under this subsection for covered OPD services (or groups of services), including covered OPD services assigned to a comprehensive ambulatory payment classification, the Secretary—</text>
 <clause id="HE21F1F22B60849D6A6E7C47A9D4DF493"><enum>(i)</enum><text display-inline="yes-display-inline">shall, as soon as practicable, conduct a review (part of which may include a request for information) of payments for opioids and evidence-based non-opioid alternatives for pain management (including drugs and devices, nerve blocks, surgical injections, and neuromodulation) with a goal of ensuring that there are not financial incentives to use opioids instead of non-opioid alternatives;</text>
 </clause><clause id="H87FC6A9D5A204106A2005AFDD868FAEB"><enum>(ii)</enum><text display-inline="yes-display-inline">may, as the Secretary determines appropriate, conduct subsequent reviews of such payments; and</text> </clause><clause id="H34AB0C2D920A4450BE16F2E0AF312440"><enum>(iii)</enum><text display-inline="yes-display-inline">shall consider the extent to which revisions under this subsection to such payments (such as the creation of additional groups of covered OPD services to classify separately those procedures that utilize opioids and non-opioid alternatives for pain management) would reduce payment incentives to use opioids instead of non-opioid alternatives for pain management.</text>
 </clause></subparagraph><subparagraph id="HE19656945E1645688B147CEBED8872BD"><enum>(B)</enum><header>Priority</header><text display-inline="yes-display-inline">In conducting the review under clause (i) of subparagraph (A) and considering revisions under clause (iii) of such subparagraph, the Secretary shall focus on covered OPD services (or groups of services) assigned to a comprehensive ambulatory payment classification, ambulatory payment classifications that primarily include surgical services, and other services determined by the Secretary which generally involve treatment for pain management.</text>
 </subparagraph><subparagraph id="H6F26592488184FE7926734CFC72F5886"><enum>(C)</enum><header>Revisions</header><text display-inline="yes-display-inline">If the Secretary identifies revisions to payments pursuant to subparagraph (A)(iii), the Secretary shall, as determined appropriate, begin making such revisions for services furnished on or after January 1, 2020. Revisions under the previous sentence shall be treated as adjustments for purposes of application of paragraph (9)(B).</text>
 </subparagraph><subparagraph id="HC2F8A96E4446496BAAC0B840FDFF0890"><enum>(D)</enum><header>Rules of construction</header><text display-inline="yes-display-inline">Nothing in this paragraph shall be construed to preclude the Secretary—</text> <clause id="H505647402BC646C6A1C681343B28523C"><enum>(i)</enum><text>from conducting a demonstration before making the revisions described in subparagraph (C); or</text>
 </clause><clause id="H8DD0ECA9B6454314917EB101C69C40AE"><enum>(ii)</enum><text>prior to implementation of this paragraph, from changing payments under this subsection for covered OPD services (or groups of services) which include opioids or non-opioid alternatives for pain management.</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="HE2EAA48C891A49D89B5F38F96CAB9F75"><enum>(b)</enum><header>Ambulatory surgical centers</header><text display-inline="yes-display-inline">Section 1833(i) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">42 U.S.C. 1395l(i)</external-xref>) is amended by adding at the end the following new paragraph:</text>
				<quoted-block display-inline="no-display-inline" id="HC172F7022D7C42CB80D2C0FC45C9DCE6" style="OLC">
 <paragraph id="HA48ABABF798541198562057BFA78F31A"><enum>(8)</enum><text display-inline="yes-display-inline">The Secretary shall apply the provisions of paragraph (22) of section 1833(t), including the second sentence of subparagraph (C) of such paragraph, to payment for services under this subsection in an appropriate manner (as determined by the Secretary).</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
			</subsection></section><section id="HB2F0810F5C6945889722E61774A34C79" section-type="subsequent-section"><enum>4.</enum><header>Expanding access under the Medicare program to addiction treatment in Federally qualified health
			 centers and rural health clinics</header>
 <subsection id="H51B15302B89844F4BDE1B48C21770459"><enum>(a)</enum><header>Federally qualified health centers</header><text display-inline="yes-display-inline">Section 1834(o) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395m">42 U.S.C. 1395m(o)</external-xref>) is amended by adding at the end the following new paragraph:</text>
				<quoted-block display-inline="no-display-inline" id="H50413361599948DEB887DFE42C81EB9E" style="OLC">
					<paragraph id="HE7D96EA285294001A497E1989CF2B8E0"><enum>(3)</enum><header>Additional payments for certain FQHCs with practitioners receiving DATA 2000 certification</header>
 <subparagraph id="H822E2FFC840E49CB884AE27B92476EE9"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">In the case of a Federally qualified health center with respect to which, beginning January 1, 2019, Federally-qualified health center services (as defined in section 1861(aa)(3)) are furnished by a health care practitioner who first receives on or after such date a registration or waiver under section 303(g) of the Controlled Substances Act to prescribe or dispense methadone, buprenorphine, or suboxone for the purpose of maintenance or detoxification treatment, the Secretary shall, subject to availability of funds under subparagraph (B), make a payment (in accordance with such timing, method, and procedures as specified by the Secretary) to such Federally qualified health center in an amount determined by the Secretary, based on an approximation of the cost to receive training for purposes of such registration or waiver, as applicable. For purposes of the previous sentence, a Federally-qualified health center shall apply for a payment described in such sentence at such time and in such manner as specified by the Secretary and may apply for such a payment for each practitioner furnishing such services at such center who is described in such sentence.</text>
 </subparagraph><subparagraph id="H5620779A3BB045F3AAA30066878ED7C7"><enum>(B)</enum><header>Funding</header><text display-inline="yes-display-inline">For purposes of making payments under this paragraph, there are appropriated, out of amounts in the Treasury not otherwise appropriated, $6,000,000, which shall remain available until expended.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H2F59F107C859425A9F2D778FAF6C2F67"><enum>(b)</enum><header>Rural health clinic</header><text display-inline="yes-display-inline">Section 1833 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395l">42 U.S.C. 1395l</external-xref>) is amended—</text> <paragraph id="HB0FE856D341D43F4997173384E71C531"><enum>(1)</enum><text display-inline="yes-display-inline">by redesignating the subsection (z) relating to medical review of spinal subluxation services as subsection (aa); and</text>
 </paragraph><paragraph id="H4CC44F69BAF743E882D9C992866E4D26"><enum>(2)</enum><text>by adding at the end the following new subsection:</text> <quoted-block display-inline="no-display-inline" id="H7CE8A831A3D94467AF83DD3E04723E3F" style="OLC"> <subsection id="H78928194D4E54D5186D2E08EAF3A8E5E"><enum>(bb)</enum><header>Additional payments for certain rural health clinics with practitioners receiving DATA 2000 certification</header> <paragraph id="HEDDA4644DD5C4D89A43453AA8C946E74"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">In the case of a rural health clinic with respect to which, beginning January 1, 2019, rural health clinic services (as defined in section 1861(aa)(1)) are furnished by a health care practitioner who first receives on or after such date a registration or waiver under section 303(g) of the Controlled Substances Act to prescribe or dispense methadone, buprenorphine, or suboxone for the purpose of maintenance or detoxification treatment, the Secretary shall, subject to availability of funds under subparagraph (B), make a payment (in accordance with such timing, method, and procedures as specified by the Secretary) to such rural health clinic in an amount determined by the Secretary, based on an approximation of the cost to receive training for purposes of such registration or waiver, as applicable. For purposes of the previous sentence, a rural health clinic shall apply for a payment described in such sentence at such time and in such manner as specified by the Secretary and may apply for such a payment for each practitioner furnishing such services at such clinic who is described in such sentence.</text>
 </paragraph><paragraph id="H4CE7D6FB7E3E4D059EBD33F4906548BF"><enum>(2)</enum><header>Funding</header><text display-inline="yes-display-inline">For purposes of making payments under this subsection, there are appropriated, out of amounts in the Treasury not otherwise appropriated, $2,000,000, which shall remain available until expended.</text></paragraph></subsection><after-quoted-block>.</after-quoted-block></quoted-block>
				</paragraph></subsection></section><section id="HBD9D326BB68A4C898CDF8B3663132139"><enum>5.</enum><header>Studying the availability of supplemental benefits designed to treat or prevent substance use
			 disorders under Medicare Advantage plans</header>
 <subsection id="H8932606D623C498FA6CEC173289B0F0B"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 2 years after the date of the enactment of this Act, the Secretary of Health and Human Services (in this section referred to as the <quote>Secretary</quote>) shall submit to Congress a report on the availability of supplemental health care benefits (as described in section 1852(a)(3)(A) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-22">42 U.S.C. 1395w–22(a)(3)(A)</external-xref>)) designed to treat or prevent substance use disorders under Medicare Advantage plans offered under part C of title XVIII of such Act. Such report shall include the analysis described in subsection (c) and any differences in the availability of such benefits under specialized MA plans for special needs individuals (as defined in section 1859(b)(6) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-28">42 U.S.C. 1395w–28(b)(6)</external-xref>)) offered to individuals entitled to medical assistance under title XIX of such Act and other such Medicare Advantage plans.</text>
 </subsection><subsection id="HE7CF742A0CBE4214A72ED63B7C6E3E2A"><enum>(b)</enum><header>Consultation</header><text>The Secretary shall develop the report described in subsection (a) in consultation with relevant stakeholders, including—</text>
 <paragraph id="H56CE3B72106B4CCA8F224B4DF3B1CAB0"><enum>(1)</enum><text>individuals entitled to benefits under part A or enrolled under part B of title XVIII of the Social Security Act;</text>
 </paragraph><paragraph id="H56C9AA2BB46D4AC9B67C64B391A43C73"><enum>(2)</enum><text>entities who advocate on behalf of such individuals;</text> </paragraph><paragraph id="HD2C3CCA7DE4D462E9D12CF8A63C9D229"><enum>(3)</enum><text>Medicare Advantage organizations;</text>
 </paragraph><paragraph id="H625A9F360B984E34AF2A5365DD9057A5"><enum>(4)</enum><text>pharmacy benefit managers; and</text> </paragraph><paragraph id="H45667CF9439C4639B97194BF8B6CF438"><enum>(5)</enum><text>providers of services and suppliers (as such terms are defined in section 1861 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x</external-xref>)).</text>
 </paragraph></subsection><subsection id="HA6DCEB6149DD40318EE255E27458C87F"><enum>(c)</enum><header>Contents</header><text>The report described in subsection (a) shall include an analysis on the following:</text> <paragraph id="H3490A35F5D8F439B89458973D6017293"><enum>(1)</enum><text>The extent to which plans described in such subsection offer supplemental health care benefits relating to coverage of—</text>
 <subparagraph id="H0036EB4609024B9BB3C3B8B81EB67ABC"><enum>(A)</enum><text>medication-assisted treatments for opioid use, substance use disorder counseling, peer recovery support services, or other forms of substance use disorder treatments (whether furnished in an inpatient or outpatient setting); and</text>
 </subparagraph><subparagraph id="H140C585DEFBE4A67914DF4E9216E692B"><enum>(B)</enum><text>non-opioid alternatives for the treatment of pain.</text> </subparagraph></paragraph><paragraph id="H49D178AC0F9F462F96E976FBA47B5024"><enum>(2)</enum><text>Challenges associated with such plans offering supplemental health care benefits relating to coverage of items and services described in subparagraph (A) or (B) of paragraph (1).</text>
 </paragraph><paragraph id="HB166BCAE42A1408A9A107070BA05E675"><enum>(3)</enum><text display-inline="yes-display-inline">The impact, if any, of increasing the applicable rebate percentage determined under section 1854(b)(1)(C) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-24">42 U.S.C. 1395w–24(b)(1)(C)</external-xref>) for plans offering such benefits relating to such coverage would have on the availability of such benefits relating to such coverage offered under Medicare Advantage plans.</text>
 </paragraph><paragraph id="HCC209AEC3CAC4BDEAE2EFCDB82D70061"><enum>(4)</enum><text display-inline="yes-display-inline">Potential ways to improve upon such coverage or to incentivize such plans to offer additional supplemental health care benefits relating to such coverage.</text>
				</paragraph></subsection></section><section id="H467EED5D9A8243FAAFA434D7C46A43DF" section-type="subsequent-section"><enum>6.</enum><header>Clinical psychologist services models under the Center for Medicare and Medicaid Innovation; GAO
			 study and report</header>
 <subsection id="HAF7AD9769AE547E6A33B7BB70C9B487C"><enum>(a)</enum><header>CMI models</header><text display-inline="yes-display-inline">Section 1115A(b)(2)(B) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1315a">42 U.S.C. 1315a(b)(2)(B)</external-xref>) is amended by adding at the end the following new clauses:</text>
				<quoted-block display-inline="no-display-inline" id="HFBD6BE6447B24E8592B3FA8ADEEE1E76" style="OLC">
 <clause id="H6E01F80EE5A44DF586FC91E0C6CE6790"><enum>(xxv)</enum><text display-inline="yes-display-inline">Supporting ways to familiarize individuals with the availability of coverage under part B of title XVIII for qualified psychologist services (as defined in section 1861(ii)).</text>
 </clause><clause id="H91EDE2D9D9124F7997383F0DE7E56D5F"><enum>(xxvi)</enum><text display-inline="yes-display-inline">Exploring ways to avoid unnecessary hospitalizations or emergency department visits for mental and behavioral health services (such as for treating depression) through use of a 24-hour, 7-day a week help line that may inform individuals about the availability of treatment options, including the availability of qualified psychologist services (as defined in section 1861(ii)).</text></clause><after-quoted-block>.</after-quoted-block></quoted-block>
 </subsection><subsection id="H0CF8156F77A148D394AAABA57369091B"><enum>(b)</enum><header>GAO study and report</header><text>Not later than 18 months after the date of the enactment of this Act, the Comptroller General of the United States shall conduct a study, and submit to Congress a report, on mental and behavioral health services under the Medicare program under title XVIII of the Social Security Act, including an examination of the following:</text>
 <paragraph id="HC43E99A9745C47EF95C7E0A5CFD0FFCD"><enum>(1)</enum><text>Information about services furnished by psychiatrists, clinical psychologists, and other professionals.</text>
 </paragraph><paragraph id="H89514E7B8D2948409737CAE5D71D983E"><enum>(2)</enum><text display-inline="yes-display-inline">Information about ways that Medicare beneficiaries familiarize themselves about the availability of Medicare payment for qualified psychologist services (as defined in section 1861(ii) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(ii)</external-xref>)) and ways that the provision of such information could be improved.</text>
				</paragraph></subsection></section><section id="HC0BA89137FEB4F61A628AE240ED3A305"><enum>7.</enum><header>Pain management study</header>
 <subsection id="HB446E17513134CBD867865771ED8D3C7"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the <quote>Secretary</quote>) shall conduct a study and submit to the Committee on Ways and Means and the Committee on Energy and Commerce of the House of Representatives and the Committee on Finance of the Senate a report containing recommendations on whether and how payment to providers and suppliers of services and coverage related to the use of multi-disciplinary, evidence-based, non-opioid treatments for acute and chronic pain management for individuals entitled to benefits under part A or enrolled under part B of title XVIII of the Social Security Act should be revised. The Secretary shall make such report available on the public website of the Centers for Medicare &amp; Medicaid Services.</text>
 </subsection><subsection id="HFF4CAE084854425F92AE8BE5B15A2E0C"><enum>(b)</enum><header>Consultation</header><text display-inline="yes-display-inline">In developing the report described in subsection (a), the Secretary shall consult with—</text> <paragraph id="H789D3DD8211E493A86A2598CAD271498"><enum>(1)</enum><text>relevant agencies within the Department of Health and Human Services;</text>
 </paragraph><paragraph id="H4DD92AFC87FD44E5B83FC3B77CF77DBD"><enum>(2)</enum><text display-inline="yes-display-inline">licensed and practicing osteopathic and allopathic physicians, behavioral health practitioners, physician assistants, nurse practitioners, dentists, pharmacists, and other providers of health services;</text>
 </paragraph><paragraph id="HF64983298B4447C88E48CC5FF40E5340"><enum>(3)</enum><text display-inline="yes-display-inline">providers and suppliers of services (as such terms are defined in section 1861 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x</external-xref>));</text>
 </paragraph><paragraph id="H587AA59195A94009987B0031A8C719AF"><enum>(4)</enum><text>substance abuse and mental health professional organizations;</text> </paragraph><paragraph id="H939836C95A4A4C77AE6C275B48B72E42"><enum>(5)</enum><text>pain management professional organizations and advocacy entities, including individuals who personally suffer chronic pain;</text>
 </paragraph><paragraph id="H98197913DDA9429F88192048A466D545"><enum>(6)</enum><text>medical professional organizations and medical specialty organizations;</text> </paragraph><paragraph id="HB49AD002E2094268AEF790F7EDE7279B"><enum>(7)</enum><text>licensed health care providers who furnish alternative pain management services;</text>
 </paragraph><paragraph id="H3D3297C1372D411F81889D0E00282D56"><enum>(8)</enum><text display-inline="yes-display-inline">organizations with expertise in the development of innovative medical technologies for pain management;</text>
 </paragraph><paragraph id="HE156E7792E4E41B2B6C5D39E46B27BEC"><enum>(9)</enum><text>beneficiary advocacy organizations; and</text> </paragraph><paragraph id="H7A6E29AC9E434C8CAB3AD37906D8DC8A"><enum>(10)</enum><text display-inline="yes-display-inline">other organizations with expertise in the assessment, diagnosis, treatment, and management of pain, as determined appropriate by the Secretary.</text>
 </paragraph></subsection><subsection id="H94D1613A61E2455A8E9DB7F12B0BB190"><enum>(c)</enum><header>Contents</header><text display-inline="yes-display-inline">The report described in subsection (a) shall include the following:</text> <paragraph id="H7EF7D013BC3A46DB88D17FFAA1B724A4"><enum>(1)</enum><text>The recommendations described in subsection (d).</text>
 </paragraph><paragraph id="HB5F265C3E36D448FA9D9B953A956317D"><enum>(2)</enum><text>The impact analysis described in subsection (e).</text> </paragraph><paragraph commented="no" id="H387EF1AF71F04E46BD3482C69E551C9B"><enum>(3)</enum><text display-inline="yes-display-inline">An assessment of pain management guidance published by the Federal Government that may be relevant to coverage determinations or other coverage requirements under title XVIII of the Social Security Act. Such assessment shall consider incorporating into such guidance relevant elements of the <quote>Va/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain</quote> published in February 2017 by the Department of Veterans Affairs and Department of Defense, including adoption of elements of the Department of Defense and Veterans Administration pain rating scale.</text>
 </paragraph><paragraph id="H0EC0ACA8C6B54AC8AE6B15E5B30DC281"><enum>(4)</enum><text>An evaluation of the following:</text> <subparagraph id="HBAFA90E8FED846D58EAAB8793D1D6874"><enum>(A)</enum><text>Barriers inhibiting individuals entitled to benefits under part A or enrolled under part B of such title from accessing treatments and technologies described in subparagraphs (A) through (F) of paragraph (6).</text>
 </subparagraph><subparagraph id="HDB461FA490024AC9BABEE2779164B0CA"><enum>(B)</enum><text display-inline="yes-display-inline">Potential legislative and administrative changes under such title to improve individuals’ access to items and services currently covered under such title and used for the treatment of pain, such as cognitive behavioral interventions, physical therapy, occupational therapy, physical medicine, biofeedback therapy, and chiropractic therapy, and other pain treatments services furnished in a hospital or post-acute care setting.</text>
 </subparagraph><subparagraph id="H77FB555E6BC248FA87307E5785FA06FC"><enum>(C)</enum><text display-inline="yes-display-inline">Costs and benefits associated with potential expansion of coverage under such title to include items and services not covered under such title that may be used for the treatment of pain, such as acupuncture, therapeutic massage, and items and services furnished by integrated pain management programs.</text>
 </subparagraph></paragraph><paragraph id="HFC5001C5306E4FC0A9CDE5B5697BD6D1"><enum>(5)</enum><text>An analysis on payment and coverage under title XVIII of the Social Security Act with respect to the following:</text>
 <subparagraph id="H9ECD32FEDD4A4E588C1FF1C288978DE2"><enum>(A)</enum><text>Evidence-based treatments and technologies for chronic or acute pain, including such treatments that are covered, not covered, or have limited coverage under such title.</text>
 </subparagraph><subparagraph id="H9D76D087737242D98A730CDB84855529"><enum>(B)</enum><text>Evidence-based treatments and technologies that monitor substance use withdrawal and prevent overdoses of opioids.</text>
 </subparagraph><subparagraph id="H0DFB577D511A472DA01B60B84EA8B5E5"><enum>(C)</enum><text>Evidence-based treatments and technologies that treat substance use disorders.</text> </subparagraph><subparagraph commented="no" id="H7D2D627D053249C89F9789E6FF793AFC"><enum>(D)</enum><text display-inline="yes-display-inline">Items and services furnished by practitioners through a multi-disciplinary treatment model for pain management, including the patient-centered medical home.</text>
 </subparagraph><subparagraph id="HFFFBEA2676F94FD4A4A0DA5B9D7F73DF"><enum>(E)</enum><text display-inline="yes-display-inline">Medical devices, non-opioid based drugs, and other therapies (including interventional and integrative pain therapies) approved or cleared by the Food and Drug Administration for the treatment of pain.</text>
 </subparagraph><subparagraph id="H9430EC12D9F2491086FA36D5B0ABAA3D"><enum>(F)</enum><text display-inline="yes-display-inline">Items and services furnished to beneficiaries with psychiatric disorders, substance use disorders, or who are at risk of suicide, or have comorbidities and require consultation or management of pain with one or more specialists in pain management, mental health, or addiction treatment.</text>
 </subparagraph></paragraph></subsection><subsection id="H464D28F3B6A14D7B8BD2D29E4143494E"><enum>(d)</enum><header>Recommendations</header><text>The recommendations described in this subsection are, with respect to individuals entitled to benefits under part A or enrolled under part B of title XVIII of the Social Security Act, legislative and administrative recommendations on the following:</text>
 <paragraph id="H611934C59CB04A2C94DA2DC1F3A5733E"><enum>(1)</enum><text display-inline="yes-display-inline">Options for additional coverage of pain management therapies without the use of opioids, including interventional pain therapies, and options to augment opioid therapy with other clinical and complementary, integrative health services to minimize the risk of substance use disorder, including in a hospital setting.</text>
 </paragraph><paragraph id="HB5C5643FA7D842F4B973F51DE40496C6"><enum>(2)</enum><text display-inline="yes-display-inline">Options for coverage and payment modifications of medical devices and non-opioid based pharmacological and non-pharmacological therapies (including interventional and integrative pain therapies) approved or cleared by the Food and Drug Administration for the treatment of pain as an alternative or augment to opioid therapy.</text>
 </paragraph><paragraph id="HC3262B9916DB4C909102EF7630234E75"><enum>(3)</enum><text display-inline="yes-display-inline">Treatment strategies for beneficiaries with psychiatric disorders, substance use disorders, or who are at risk of suicide, and treatment strategies to address health disparities related to opioid use and opioid abuse treatment.</text>
 </paragraph><paragraph id="HC9B1076610164977AF0D8E49E0F78947"><enum>(4)</enum><text display-inline="yes-display-inline">Treatment strategies for beneficiaries with comorbidities who require a consultation or comanagement of pain with one or more specialists in pain management, mental health, or addiction treatment, including in a hospital setting.</text>
 </paragraph><paragraph id="H6C8839C4EE9E422D95AE4E41F79D2696"><enum>(5)</enum><text display-inline="yes-display-inline">Coadministration of opioids and other drugs, particularly benzodiazepines.</text> </paragraph><paragraph id="HDA2A6D03DD2E4116AB1E6254BDD64B34"><enum>(6)</enum><text display-inline="yes-display-inline">Appropriate case management for beneficiaries who transition between inpatient and outpatient hospital settings, or between opioid therapy to non-opioid therapy, which may include the use of care transition plans.</text>
 </paragraph><paragraph id="H5BC737BF92D44CAB8C65E5582F216E6A"><enum>(7)</enum><text display-inline="yes-display-inline">Outreach activities designed to educate providers of services and suppliers under the Medicare program and individuals entitled to benefits under part A or under part B of such title on alternative, non-opioid therapies to manage and treat acute and chronic pain.</text>
 </paragraph><paragraph id="HA5DDD7C5BDB2411897C64E5324F2DBB5"><enum>(8)</enum><text>Creation of a beneficiary education tool on alternatives to opioids for chronic pain management.</text> </paragraph></subsection><subsection id="HC93E64BC5FCA49498F05F82C3D1C33C0"><enum>(e)</enum><header>Impact analysis</header><text display-inline="yes-display-inline">The impact analysis described in this subsection consists of an analysis of any potential effects implementing the recommendations described in subsection (d) would have—</text>
 <paragraph id="H577FEA16AC9C40FC82A394FCED80E160"><enum>(1)</enum><text>on expenditures under the Medicare program; and</text> </paragraph><paragraph id="HEA9145C63D724AFE8594B2C6B2513385"><enum>(2)</enum><text>on preventing or reducing opioid addiction for individuals receiving benefits under the Medicare program.</text>
				</paragraph></subsection></section></legis-body></bill>


